Increased serum iron levels and infectious complications after liver transplantation

Clinical Infectious Diseases

Volumn 51, Issue 3, 2010, Pages

  Chow, Jennifer K ^a   Werner, Barbara G ^c   Ruthazer, Robin ^b   Snydman, David R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FERRITIN; IRON; MONOCLONAL ANTIBODY; OKT 3; TRANSFERRIN;

ADULT; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CASE CONTROL STUDY; CYTOMEGALOVIRUS INFECTION; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FUNGAL COLONIZATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS COMPLICATION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; ADOLESCENT; AGED; BLOOD; CHEMISTRY; CHILD; COMMUNICABLE DISEASES; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK ASSESSMENT; SERUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES; FEMALE; HUMANS; INFANT; IRON; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM; YOUNG ADULT;

EID: 77954746387     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/654802     Document Type: Article

References (56)

1. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170(3):644-652.
2. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996; 23(3):468-474.
3. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW,Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59(6): 851-859.
4. Hollenbeak CS, Alfrey EJ, Souba WW. The effect of surgical site infections on outcomes and resource utilization after liver transplantation. Surgery 2001; 130(2):388-395.
5. Singh N, Gayowski T,Wagener MM, Marino IR. Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin Transplant 1997; 11(4):275-281.
6. Falagas ME, Snydman DR, George MJ, et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Transplantation 1996; 61(12):1716-1720.
7. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1997; 25(2):314-317.
8. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in ortho topic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103(2):106-113.
9. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62(7):926-934.
10. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18(2):185-195.
11. Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39(9):1293-1299.
12. Banbury MK, Brizzio ME, Rajeswaran J, Lytle BW, Blackstone EH. Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg 2006; 202(1):131-138.
13. Chang H, Hall GA, Geerts WH, Greenwood C, McLeod RS, Sher GD. Allogeneic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection. Vox Sang 2000; 78(1):13-18.
14. Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39(7):694-700.
15. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg 2002; 68(7):566-572.
16. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34(6):1608-1616.
17. Palmieri TL, Caruso DM, Foster KN, et al. Effect of blood transfusion on outcome after major burn injury: a multicenter study. Crit Care Med 2006; 34(6):1602-1607.
18. Silverboard H, Aisiku I, Martin GS, Adams M, Rozycki G, Moss M. The role of acute blood transfusion in the development of acute respiratory distress syndrome in patients with severe trauma. J Trauma 2005; 59(3):717-723.
19. Crowe WE, Maglova LM, Ponka P, Russell JM. Human cytomegalovirus- induced host cell enlargement is iron dependent. Am J Physiol Cell Physiol 2004; 287(4):C1023-C1030.
20. Romeo AM. Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem 2001; 276(26):24301-24308.
21. van Asbeck BS. Anti-HIV effect of iron chelators: differentmechanisms involved. J Clin Virol 2001; 20(3):141-147.
22. Kartikasari AE, Georgiou NA, de Geest M, et al. Iron enhances endothelial cell activation in response to cytomegalovirus or Chlamydia pneumoniae infection. Eur J Clin Invest 2006; 36(10):743-752.
23. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O. Iron-source preference of Staphylococcus aureus infections. Science 2004; 305(5690): 1626-1628.
24. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 1993; 91(5):1979-1986.
25. Bullen JJ, Wilson AB, Cushnie GH, Rogers HJ. The abolition of the protective effect of Pasteurella septica antiserum by iron compounds. Immunology 1968; 14(6):889-898.
26. Bullen JJ, Spalding PB, Ward CG, Rogers HJ. The role of Eh, pH and iron in the bactericidal power of human plasma. FEMS Microbiol Lett 1992; 73(1-2):47-52.
27. Elin RJ,Wolff SM. The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol 1974; 112(2):737-745.
28. Kluger MJ, Rothenburg BA. Fever and reduced iron: their interaction as a host defense response to bacterial infection. Science 1979; 203(4378):374-376.
29. Al Younes HM, Rudel T, Brinkmann V, Szczepek AJ, Meyer TF. Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell Microbiol 2001; 3(6):427-437.
30. Schaible UE, Collins HL, Priem F, Kaufmann SH. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 2002; 196(11):1507-1513.
31. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis 1999; 5(3):346-352.
32. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 2006; 12(12):1799-1804.
33. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29(12):987-989.
34. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004; 34(6):505-509.
35. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109(10):4586-4588.
36. Caroline L, Rosner F, Kozinn PJ. Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood 1969; 34(4):441-451.
37. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10(3):377-381.
38. Karp JE, Merz WG. Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients. J Clin Oncol 1986; 4(2):216-220.
39. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110(6): 1303-1306.
40. Lambert CC, Hunter RL. Low levels of unsaturated transferrin as a predictor of survival in pneumococcal pneumonia. Ann Clin Lab Sci 1990; 20(2):140-146.
41. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24(3):307-312.
42. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37(9): 857-864.
43. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38(8):1090-1094.
44. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119(10): 984-991.
45. Arbo MD, Snydman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med 1994; 154(23):2641-2645.
46. George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis 1991; 13(3):387-396.
47. Singh N, Wannstedt C, Keyes L, et al. Hepatic iron content and the risk of Staphylococcus aureus bacteremia in liver transplant recipients. Prog Transplant 2007; 17(4):332-336.
48. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101(7):2461-2463.
49. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001; 98(15) 8780-8785.
50. Kemna E, Pickkers P, Nemeth E, van der HH, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106(5):1864-1866.
51. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113(9):1271-1276.
52. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276(11):7811-7819.
53. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110(6):2182-2189.
54. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110(7):1037-1044.
55. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55(6): 667-674.
56. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108(12): 3730-3735.